Neuland Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹450 crore and net profit of ₹52 crore for the September 2026 quarter.
Neuland Laboratories (NSE: NEULANDLAB) closed at ₹20,642.00 on 20 Nov 2026, up 23.5% over the past year. Its market capitalisation is ₹26,483 crore and it trades at 58.5 times earnings.
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.